LA JOLLA, CALIFORNIA (October 11, 2017) – INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient’s innate immune system to attack their cancer, today announces that company president and CEO RJ Tesi MD will present at the BIO Investor 2017 Healthcare Conference. 

INmune Bio was nominated to the Buzz of BIO contest in the Early Stage Entrepreneur category, which recognizes the most innovative companies at the 2017 BIO Investor Forum.

In addition to the presentation, INmune Bio management will be available for one-on-one meetings on October 17-18.  These meetings can be scheduled directly or using the partnering system associated with the BIO Investor Conference. 

Presentation Details:

Date/Time:     Wednesday, 18 October at 2:45 p.m. PDT
Location:        Westin St. Francis on Union Square - Elizabethan A

About INmune Bio Therapeutics INmune Bio, Inc.

INmune Bio is a private clinical-stage Biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two product platforms that reengineer the patient’s innate immune system’s response to their cancer. INB03 targets myeloid derived suppressor cells (MDSC) of the tumor microenvironment that suppress the ability of the patient’s immune system to attack the tumor. INKmune is an NK therapeutic that primes the patient’s NK cells to attack their tumor. INB03 and INKmune can be used in a precision medicine approach to threat a wide variety of hematologic malignancies and solid tumors.  INB03 and INKmune can be used alone, together or in combination with other anti-cancer therapies. 

To learn more, please visit 

Forward looking statements: This press release contains certain "forward-looking statements." Such statements may include statements relating the leadership of the company and other statements relating to future events or to the company's future financial performance and are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects,” "anticipates," “projects," "predicts," "estimates," "aims,” "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's Private Placement Memorandum. The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

INmune Bio Contact:                                   
David Moss
This email address is being protected from spambots. You need JavaScript enabled to view it.

Communications Contact:
NetworkNewsWire (NNW)
New York, New York

212.418.1217 Office
This email address is being protected from spambots. You need JavaScript enabled to view it.


This website uses cookies to facilitate the use of the website, improve its performance and security, and personalize the proposed content.